Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System.

Notably, the number of reported cases of PCSK9 inhibitor regimens fluctuated without an apparent trend, especially a peak in 2018, while reports of statins appeared an increasing trend over years.

also in 63,971 other papers